ORGANIZATION

Drug Damage Watchdog Opposes Legislation of Conditional Approval System, Calls for Tougher Rules on Ads

March 13, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Medwatcher Japan, a citizen’s drug damage watchdog, opposed the legislation of the conditional early approval system, which will be included in the draft bill for the amendment of the Pharmaceuticals and Medical Devices (PMD) Law that the health ministry plans…

To read the full story

MHLW to Impose Administrative Fines Only on Misleading Ads, Eyes 4.5% Charge: PMD Law
February 28, 2019

ORGANIZATION

EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…